Cannabis glaucoma treatment enters phase 1 trials

Cannabis Technologies Inc.(CTI) says that its cannabis-based topical anti-glaucoma medication has advanced to phase 1 clinical testing.

The company says its proprietary compound, CTI 085, has showed efficacy in lowering intraocular pressure in animal models.

"Our objective was to develop a safer; cannabis based topical anti-glaucoma formulation without systemic side effects,” Dr. Hossain, Chief Scientific Officer said. “We are pleased to have successfully completed our pre-clinical trials which are in the process of the clinical development of the formulation".

CTI is a biopharmaceutical drug discovery and development company focused on the pharmacology and therapeutic potential of cannabinoids for ophthalmic, cancer, inflammation and pain.